@article{fdi:010057157,
  title = {{T}olerability of mefloquine intermittent preventive treatment for malaria in {HIV}-infected pregnant women in {B}enin},
  author = {{D}enoeud {N}dam, {L}ise and {C}l{\'e}ment, {M}. {C}. and {B}riand, {V}al{\'e}rie and {A}kakpo, {J}. and {A}gossou, {V}. {K}. and {A}tadokp{\'e}d{\'e}, {F}. and {D}ossou-{G}b{\'e}t{\'e}, {L}. and {K}omongui, {D}. {G}. and {A}fangnihoun, {A}. and {G}irard, {P}. {M}. and {Z}annou, {D}. {M}. and {C}ot, {M}ichel},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjective: {T}o investigate the tolerability of mefloquine intermittent preventive treatment ({MQ} {IPT}p) for malaria in {HIV}-infected pregnant women compared with {HIV}-negative women. {D}esign: {P}rospective cohort study comparing samples of {HIV}-negative and {HIV}- infected pregnant women from 2 clinical trials conducted in {B}enin. {M}ethods: {O}ne hundred and three {HIV}-infected women from the ongoing {PACOME} trial were compared with 421 {HIV}-negative women from a former trial, both trials aiming to evaluate the efficacy and tolerability of {MQ} {IPT}p, administered at the dose of 15 mg/kg. {D}escriptive analysis compared the proportion of women reporting at least 1 adverse reaction, according to {HIV} status. {M}ultilevel logistic regression identified factors associated with the probability of reporting an adverse reaction for each {MQ} intake. {R}esults: {D}izziness and vomiting were the most frequent adverse reactions. {A}dverse reactions were less frequent in {HIV}-infected women (65% versus 78%, {P} = 0.009). {I}n multilevel analysis, {HIV} infection [odds ratio ({OR}) = 0.23, 95% confidence interval ({CI}) = 0.08 to 0.61] decreased the risk for adverse reactions, whereas detectable viral load ({OR} = 2.46, 95% {CI} = 1.07 to 5.66), first intake (versus further intakes, {OR} = 5.26, 95% {CI} = 3.70 to 7.14), older age ({OR} = 1.62, 95% {CI} = 1.13 to 2.32), and higher education level ({OR} = 1.71, 95% {CI} = 1.12 to 2.61) increased the risk. {M}oderate and severe adverse reactions were more frequent when antiretrovirals were started concomitantly with a {MQ} intake. {C}onclusions: {T}his study provides reassuring data on the use of {MQ} {IPT}p in {HIV}-infected pregnant women. {H}owever frequent, adverse reactions remained moderate and did not impair adherence to {MQ} {IPT}p. {I}n this high-risk group, {MQ} might be an acceptable alternative in case sulfadoxine-pyrimethamine loses its efficacy for intermittent preventive treatment.},
  keywords = {{HIV} ; malaria ; pregnancy ; mefloquine ; drug tolerance ; {B}enin},
  booktitle = {},
  journal = {{J}aids-{J}ournal of {A}cquired {I}mmune {D}eficiency {S}yndromes},
  volume = {61},
  numero = {1},
  pages = {64--72},
  ISSN = {1525-4135},
  year = {2012},
  DOI = {10.1097/{QAI}.0b013e3182615a58},
  URL = {https://www.documentation.ird.fr/hor/fdi:010057157},
}